HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Derek von Haag Royce Calhoun David Follette Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lee, B. E. Articles by Follette, D. Search for Related Content PubMed PubMed Citation Articles by Lee, B. E. Articles by Follette, D. Related Collections Mediastinum

J Thorac Cardiovasc Surg 2007;133:746-752
© 2007 The American Association for Thoracic Surgery

General Thoracic Surgery

Advances in positron emission tomography technology have increased the need for surgical staging in non–small cell lung cancer

^a Division of Cardiothoracic Surgery, University of California at Davis, Cancer Center, Sacramento, Calif
^b University of California at Davis, Cancer Center, Sacramento, Calif
^c Department of Internal Medicine, Division of Oncology, University of California at Davis, Cancer Center, Sacramento, Calif.

Read at the Thirty-second Annual Meeting of the Western Thoracic Surgical Association, Sun Valley, Idaho, June 21-24, 2006.

Received for publication June 18, 2006; revisions received October 2, 2006; accepted for publication October 24, 2006.

^_* Address for reprints: David Follette, MD, Division of Cardiothoracic Surgery, University of California at Davis, UC Davis Cancer Center, 4501 X St, Sacramento, CA 95817. (Email: david.follette{at}ucdmc.ucdavis.edu).

Objectives: Pretreatment staging of patients with non–small cell lung cancer is critically important in determining an appropriate treatment plan. As positron emission tomography (PET) and computed tomography (CT) are proven complementary modalities in clinical staging, recent advances in PET technology have brought forth integrated PET/CT as the new standard. We tested the hypothesis that improvements in PET technology have not increased the sensitivity or specificity of PET in the staging of non–small cell lung cancer to an extent that surgical staging is no longer required.

Methods: This is a retrospective, single-institution review of 336 patients from 1995 to 2005 with biopsy-proven non–small cell lung cancer who underwent [¹⁸F] fluoro-2-deoxy-D-glucose–PET before mediastinal lymph node sampling by cervical mediastinoscopy or thoracotomy. Clinical records, histopathologic reports, and PET findings were reviewed. Data were analyzed by the Pearson ² test.

Results: Within the study population, 210 patients had routine PET and 126 had integrated PET/CT. For detecting mediastinal metastases the sensitivities of PET versus integrated PET/CT were 61.1% versus 85.7% (P < .05), specificities were 94.3% versus 80.6% (P < .001), positive predictive values were 68.8% versus 55.8%, negative predictive values were 92.1% versus 95.2%, and overall accuracy was 88.6% versus 81.7%.

Conclusions: Improvements in PET technology have increased integrated PET/CT sensitivity at the cost of significantly decreased specificity. Although it may appear that integrated PET/CT incurs fewer false negative results, the dramatic increase in false positive results reinforces the notion that integrated PET/CT should be used only as an adjunct to clinical staging and that surgical staging remains the gold standard in non–small cell lung cancer.

This article has been cited by other articles:

				S. S. Groth, B. A. Whitson, J. D'Cunha, M. A. Maddaus, M. Alsharif, and R. S. Andrade Endobronchial ultrasound-guided fine-needle aspiration of mediastinal lymph nodes: a single institution's early learning curve. Ann. Thorac. Surg., October 1, 2008; 86(4): 1104 - 1109. [Abstract] [Full Text] [PDF]

				S. M Woolley and P. B. Rajesh The Use of PET and PET/CT Scanning in Lung Cancer Asian Cardiovasc Thorac Ann, October 1, 2008; 16(5): 353 - 354. [Full Text] [PDF]

				B. E. Lee, J. Redwine, C. Foster, E. Abella, T. Lown, D. Lau, and D. Follette Mediastinoscopy might not be necessary in patients with non-small cell lung cancer with mediastinal lymph nodes having a maximum standardized uptake value of less than 5.3 J. Thorac. Cardiovasc. Surg., March 1, 2008; 135(3): 615 - 619. [Abstract] [Full Text] [PDF]